Shockwave Reducer
This product is available only in Greece and Cyprus
The Shockwave Reducer is an innovative and specialized medical device designed to alleviate symptoms of refractory angina by modifying blood flow in the coronary sinus. It can be implanted in patients who no longer respond to standard medical therapy and are not suitable candidates for further revascularization procedures, such as coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).
Implanted via a minimally invasive, transvenous procedure, the Reducer is positioned in the coronary sinus, where it creates a controlled narrowing that redistributes venous blood flow. This targeted increase in coronary sinus pressure enhances perfusion to ischemic areas of the myocardium, thereby reducing the frequency and severity of angina episodes.
This therapy is intended for patients with long-standing, stable refractory angina who have exhausted conventional treatment options. It has been shown to significantly improve symptoms and overall quality of life, particularly in individuals for whom pharmacologic and interventional strategies have proven ineffective.
Key Benefits
• Catheter-based, minimally invasive implantation;
• Enhances myocardial perfusion via targeted hemodynamic modulation;
• Reduces the burden of chronic angina;
• Supports improved functional capacity and quality of life;
• Demonstrated safety and tolerability in appropriate patients.
The efficacy of the Shockwave Reducer has been confirmed in multiple clinical studies.
In the COSIRA randomized controlled trial, 71% of patients experienced improvement in at least one Canadian Cardiovascular Society (CCS) angina class at 6 months.
Long-term results from the REDUCER-I post-market study showed that 82% of patients maintained clinical benefit at 2 years, confirming the durability of symptom relief.
Manufacturer:
Need help?
